Biotechnology

Newly Published Data Reinforce Robust Prognostic Associations for DiviTum(R) TKa in Metastatic Breast Cancer

February 12, 2026 2:50 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces that results from the prospective PDM‑MBC (Personalised Disease Monitoring in Metastatic Breast Cancer) study have been published in Breast Cancer Research and Treatment. The results show that DiviTum® TKa provides robust prognostic information on both progression‑free and overall survival across several early time...

Read more

Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update

February 12, 2026 2:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the third quarter of 2025 and provided a business update. "The fourth quarter of 2025 was marked by continued execution on our strategy, focusing on advancing mitazalimab towards initiation of registrational trials, strengthening the scientific foundation of our...

Read more

With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation

February 10, 2026 4:20 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes transforming abundant feedstock into valuable nutraceuticals and new medicines - announced the launch of a redesigned corporate website and updated visual identity, reflecting the company's refined strategic focus on pharmaceutical and nutraceutical markets. The update follows the company's previously communicated decision to sharpen its commercial scope toward...

Read more

IGC Pharma Announces Equity Research Update by Alliance Global Partners

February 10, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated equity research report covering the Company. The report reiterates a Buy rating and includes a price target of $3.00 per share. All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma....

Read more

Calbiotech and Liquid Biosciences Announce Strategic Collaboration to Accelerate Next-Generation Diagnostic Development

February 10, 2026 8:00 AM

Calbiotech, Inc. and Liquid Biosciences today announced a strategic collaboration focused on accelerating the development and commercialization of advanced diagnostic tests across multiple disease areas. The collaboration combines Calbiotech's assay development, regulated manufacturing, and global distribution capabilities with Liquid Biosciences' biomarker discovery and clinical innovation platform. Together, the companies aim to rapidly...

Read more

Longwood Healthcare Leaders to Host Senior Pharma and Biotech Leaders at Annual Leadership Summit, Miami CEO

February 10, 2026 7:00 AM

Longwood Healthcare Leaders will host its annual leadership summit, Miami CEO, March 12-13, 2026 at The Ritz-Carlton Key Biscayne. The off-the-record networking forum features participants across pharma, biotech, academia, regulatory, and investing communities. Thought leaders will speak in discussion panels, fireside chats, and roundtable discussions focusing on some of the most important issues facing the life sciences ecosystem today. In...

Read more

Microbix Welcomes The College of American Pathologists as a Client For Supply of QAPs for PT/EQA Programs

February 10, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, is pleased to welcome the College of America Pathologists ("CAP") as a customer for Microbix quality assessment products ("QAPs™") for use in CAP clinical laboratory proficiency-testing ("PT") programs, also commonly known as External Quality Assessments ("EQA"). The College of American Pathologists is a member-based organization...

Read more

Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting

February 9, 2026 1:00 PM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Shareholders of Faron Pharmaceuticals Ltd (business ID: 2068285-4, the "Company") are notified of the Extraordinary General Meeting (the "EGM") to be held on 2 March 2026 at 10:00 a.m. EET (Finnish time) at Biocity, meeting room "Presidentti" at Tykistökatu 6, FI-20520 Turku, Finland. The registration of attendees and the distribution of voting slips will commence at the meeting venue at 9:30 a.m....

Read more

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

February 9, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia ("GNA"). This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer's population. The GNA site is the latest addition to a clinical...

Read more

Ayrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast Asia

February 9, 2026 7:00 AM

Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced that it has appointed ACA Pharma as its exclusive distributor for Omisirge (Omidubicel-onlv) and granted ACA Pharma exclusive rights to seek registration and to distribute Omisirge across the following jurisdictions: Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines,...

Read more

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

February 5, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce that it has commenced Project Phase 2 peptide design activities with Neuland Laboratories Limited ("Neuland") under the parties' existing services agreement (please see news release dated January 8, 2026). Project Phase 2 of the collaboration focuses on the design and optimization of next-generation cell-penetrating...

Read more

Ayrmid and Ariti Sign Distribution Agreement for Omisirge(R) in Greece and Cyprus

February 5, 2026 9:00 AM

Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced that it has entered into an exclusive distribution agreement with Ariti S.A., a Greece based pharmaceutical company for the distribution of Omisirge (Omidubicel-onlv) in Greece and Cyprus. Under the terms of the agreement, Ariti will provide services to support early access schemes to Omisirge in the agreed territories, leveraging its established...

Read more

Microbix Schedules Release of Results for Q1 Fiscal 2026

February 5, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its first quarter of fiscal 2026 ended December 31, 2025 ("Q1 2026") prior to the start of trading on February 12, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q4 2025...

Read more

Ayrmid Pharma Ltd Announces Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia (SAA) Presented at TANDEM

February 5, 2026 7:00 AM

Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation, today announced further positive interim clinical results for Omisirge (Omidubicel-onlv), its advanced stem cell transplant therapy for Severe Aplastic Anemia (SAA). The data showed that patients with SAA who received Omisirge transplants experienced faster and more robust immune recovery compared with patients receiving other...

Read more

Invitation to Alligator Bioscience's Earnings Call on 12 February 2026

February 5, 2026 3:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, will publish its year-end report for 2025 on Thursday, 12 February 2026, at 8:00 a.m. CEST. On the same day, Alligator will host a webinar and conference call for investors, analysts, and media at 3:00 p.m. CEST / 9:00 a.m. EDT, where CEO Søren Bregenholt and CFO Johan Giléus will present and...

Read more

Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference

February 4, 2026 4:25 PM

Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company focused on the development of novel carbohydrate-based therapeutics, today announced that David Platt, Ph.D., Chief Executive Officer of Bioxytran, will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, February 5, 2026. Dr. Platt's formal presentation will feature a fireside-style Q&A session, with questions welcomed from the live virtual...

Read more

CORRECTION FROM SOURCE: Expert Intelligence Raises $5.8 Million Seed Round to Bring AI Decision Automation to Regulated Laboratories

February 4, 2026 1:27 PM

Expert Intelligence™, a startup building AI systems that automate expert decision-making in regulated laboratory environments, today announced it has raised a $5.8M seed round led by Sierra Ventures with participation from TSVC and Acorn Pacific Ventures. Founded by Lalin Theverapperuma, Ph.D., a veteran AI and machine learning engineer with more than 20 years of experience at Apple, Meta, Intel, and Bosch, Expert Intelligence's platform...

Read more

Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial

February 4, 2026 8:33 AM

Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the appointment of Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gon will lead the Company's commercial and business development activities, as well as its financial strategy, planning, and reporting. Mr. Gon joins Regentis at a...

Read more

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

February 4, 2026 8:30 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed that for the last 10 consecutive business days, from January 20, 2026 through February...

Read more

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant

February 4, 2026 8:00 AM

Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An...

Read more